One recent advancement is the approval of glucagon-like peptide-1 receptoragonists(GLP-1RAs) for use inadolescents.GLP-1RAs are notable for their effectiveness in weight management and in their ability to ameliorate obesity-related diseases.
Glucagon-like peptide-1 receptoragonists(GLP-1RAs) have surged to the forefront of obesity treatment due to their efficacy in weight loss and weight management across age groups, including amongadolescents[1]. However, there is limited evidence on how the use ofGLP-1RAs for obesity during adolescence may impact this critical developmental period and long-term health. There is an urgent ...
This systematic review and meta-analysis assesses the efficacy and safety of glucagon-like peptide-1 receptoragonists(GLP-1RAs) in children andadolescentswith obesity, prediabetes, or type 2 diabetes.
This review examines the growing role of glucagon-like peptide-1 receptoragonists(GLP-1RAs) in the management of pediatric obesity. Simultaneously, this study highlights the critical considerations for clinicians in administering these medications, including long-term safety, efficacy, potential adverse effects, and overall clinical utility.
As we can see from the illustration, Glp-1 Agonists And Adolescent Hunger Hormones has many fascinating aspects to explore.
GLP-1receptoragonistsfor the treatment of obesity in children andadolescents: a meta-analysis of randomized controlled trials Livia M. Romariz1 , Amanda Almeida Cavalcanti de Melo2, Emma ...
Learning Point The use ofGLP-1sis quickly and significantly expanding in the adult population and already changes are seen in theadolescentandyoung adult populations. One 2024 study found that dispensing ofGLP-1ssignificantly increased from 2020-2024 foradolescentsandyoung adults ages 12-25 years.
